House Passes Bipartisan Amendment to Increase Funding in FY19 Budget; Restores Funding to FY09 Level
Thursday, June 28, 2018 — Today, Lung Cancer Alliance hailed the passage of a bipartisan amendment in the U.S. House of Representatives that secured an additional $6 million to the Department of Defense (DOD) Lung Cancer Research Program in the FY19 budget. This move, pushed by Congressmen Rick Nolan (D-MN) and Frank LoBiondo (R-NJ), restored research funding levels from $14 million to the original $20 million funding level approved in 2009 by Congress for the Congressionally Directed Medical Research Program (CDMRP) Lung Cancer Research Program.
For the last eight years, LCA has consistently lead advocacy efforts to increase federal research funding to the original funding level through the annual appropriations process by working with members of Congress including Reps. Nolan and LoBiondo through the Congressional Lung Cancer Caucus. This is the largest lung cancer research program – public or private – outside of the National Cancer Institute.
The Lung Cancer Research Program at CDMRP has played a critical role in supporting high-impact, innovative lung cancer research within the military and general public in several areas including risk assessment, prevention, early detection, diagnosis, treatment, survivorship and outcomes.
Full details about the CDMRP can be viewed here.